XI'AN, China, Aug. 20 /Xinhua-PRNewswire/ -- Huifeng Bio-Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today announced it will be in attendance at the CPhI South America Conference, August 19-21 in Rio de Janeiro, Brazil.
"Unparalleled business opportunities for all companies involved in the pharmaceutical raw materials industry are now presenting themselves throughout South America, particularly in Brazil, " stated Jing' An Wang, CEO, Huifeng. "Huifeng is becoming recognized as a leading industry player and has much to offer the South American, as well as to the global, pharmaceutical market."
"We are excited to begin cultivating new relationships with corporations from around the world during this important conference," said Mr. Wang.
According to CPhI, there are more than 180 million people living in Brazil alone. With a rapidly emerging market second only to China and a growth rate exceeding that of the global average, South America continues to promote an attractive business arena.
Due to the rapid amount of global investment taking place in Brazil much is to be gained by establishing new business partnerships with local suppliers, buyers and manufacturers.
About CMP Information and CPhI Pharmaceutical Conferences
CMP Information, part of United Business Media plc, a London Stock Exchange listed media company, is responsible for the organization of the world's leading CPhI, ICSE, Hi and Fi series of pharmaceutical and food ingredient trade shows. CPhI is the leading international exhibition provider in the pharmaceutical ingredients and allied industries markets. This is the first CPhI conference to take place in South America.
About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB.OB)
Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's
Republic of China, develops and produces plant extracts and pharmaceutical
raw materials for use in pharmaceutical, nutraceutical and food production.
It is the leading Chinese producer of rutin and related plant-derived
chemicals in a class called flavonoids, with medicinal and other beneficial
properties. Founded in 2002, Huifeng uses proprietary patented processes to
extract rutin more efficiently than traditional extraction techniques. The
Company is diversifying its product lines through internal development,
acquisition and cooperation with scientific research organizations.
For more information, please contact:
Dan Carlson, Primary Capital LLC
Kelly Black, CEO
Premier Media Services, Inc.
|SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.|
Copyright©2008 PR Newswire.
All rights reserved